Jayne McNicol's most recent trade in Renovaro Biosciences Inc was a trade of 46,584 Option to purchase shares of common stock done . Disclosure was reported to the exchange on June 25, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Renovaro Biosciences Inc | Jayne McNicol | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 46,584 | 46,584 | - | - | Option to purchase shares of common stock | |
Renovaro Biosciences Inc | Jayne McNicol | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2024 | 52,817 | 52,817 | - | - | Option to Purchase Common Stock | |
Renovaro Biosciences Inc | Jayne McNicol | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 16,892 | 16,892 | - | - | Option to purchase shares of common stock | |
Renovaro Biosciences Inc | Jayne McNicol | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 26,498 | 26,498 | - | - | Option to purchase shares of common stock |